Dr. Reddys Laboratories Ltd.

BSE: 500124 | NSE: DRREDDY

Mid Cap | Pharmaceuticals & Drugs

1350.20

11.70 (0.87%)

< Home < Back

Dr Reddys Laboratories informs about press release

Date: 19-04-2016

Dr Reddys Laboratories has informed about a Press Release dated April 19, 2016 titled ‘ZEMBRACE SymTouch (sumatriptan injection) 3 mg, approved by the FDA in January 2016 for the acute treatment of migraine with or without aura in adults, is now commercially available in the US’.

The above information is a part of company’s filings submitted to BSE.